Artificial tears containing hyaluronic acid in dry eye syndrome treatment
https://doi.org/10.21516/2072-0076-2016-9-4-97-104
Abstract
Today, artificial tears containing hyaluronic acid are the first choice remedy in dry eye syndrome treatment. This is due to unique properties of hyaluronan, such as mucoadhesion, high hydrophilia, adaptive viscoelasticity depending on pH level, composition similar to the native tear, an ability to stimulate migration and proliferation of epitheliocytes, to affect cell diffusion, to have a protective and antioxidative effect on the cells, etc. However, while choosing artificial tear drops we have to take account not only of the presence of hyaluronan as the main ingredient, but also ofthe qualitative characteristics of its molecules, type and concentration of the buffer, presence of a preservative agent, and other factors that can weaken hyaluronan beneficial features, cause an allergy, worsen the viscoelastic properties of the solution, etc. // Russian Ophthalmological Journal, 2016; 4: 94-104. doi: 10.21516/2072-0076-2016-9-4-94-104.
About the Authors
I. A. Pronkin
S. Fyodorov Eye Microsurgery Complex
Russian Federation
Russian Federation
D. Yu. Maichuk
S. Fyodorov Eye Microsurgery Complex
Russian Federation
Russian Federation
References
1. Baudouin C. The vicious circle in dry eye syndrome: a mechanistic approach. J. Fr. Ophtalmol. 2007; 3: 239-46.
2. Hargittai I., Hargittai M. Molecular structure of hyaluronan; an introduction. Struct. Chem. 2008; 19: 697-717.
3. Yang С., Cao M., Liu H., et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J. of Biol. Chem. 2012; 287 (51): 43094-107.
4. Teping C. Drug report. Hyaluronsäure. Klin. Monbl. Augenheilkd. 2010; 227 (4); Suppl. 2: 4-14.
5. Scott J. Extracellular matrix, supramolecular organization and shape. J. Anat. 1995; 187: 259-69.
6. Lapcik L., Lapcik L., DeSmedt S. Hyaluronan: preparation, structure, properties and applications. Chem. Rev. 1998; 98: 2663-84.
7. Scott J., Cummings C., Brass A. Secondary and tertiary structures of hyaluron in aqueous solution, investigated by rotary shadowing electron microscopy and computer simulation. Biochem. J. 1991; 274: 699-705.
8. Cantor J., Nadkarni P. Hyaluronan: the Jekyll and Hyde molecule.Inflamm. Allergy Drug Targets. 2006; 5: 257-60.
9. Sindt C. A new dry eye therapy? Could hyaluronic acid be instrumental in the treatment of dry eye?Rev. Cornea Contact Lenses. 2009; 1: 12.
10. Polack F., McNiece M. The treatment of dry eye with Na Hyaluronate (Healon®). Cornea. 1982; 1(2): 133-6.
11. Andre P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHAdQ-Medical, Sweden) in European countries: retrospective study from 1997 to 2001. J. Eur. Acad. Dermatol. Venerol. 2004; 18: 422-5.
12. Milas M., Rinaudo M.Characterization and properties of hyaluronic acid (hyaluronan). Dumitriu S. ed. Polysaccharides Structural Diversity and Functional Versatility. New York: Marcel Dekker; 2005.
13. Bothner H., Wik O. Rheology of Hyaluronate.ActaOtolaryngol. Suppl. 1987; 442: 25-30.
14. Presti D., Scott J. Hyaluronan-mediated protective effect against call damage caused by enzymatically produced hydroxyl (OH) radicals is dependent on hyaluronan molecular mass. Cell biochem. Funct. 1994; 12: 281-8.
15. Pauloin T., Dutot M., Joly F., Warnet J., Rat P. High molecular weight hyaluronan decreases UVB-induced apoptosis and inflammation in human epithelial corneal cells. Mol. Vis. 2009; 15: 577-83.
16. Nishida T., Nakamura M., Mishima H., et al. Hyaluronan simulates corneal epithelial migration. Exp. Eye Res. 1991; 53: 753-8.
17. Gomes J., Amankwah R., Powell-Richards A., et al. Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br. J. Ophthalmol. 2004; 88: 821-5.
18. Inoue M., Katakami C. The effect of hyaluronic acid on corneal epithelial cell proliferation. Invest. Ophthalmol. Vis. Sci. 1993; 34: 2313-5.
19. Bucher F., Bachmann B., Bock F., et al. Impact of hyaluronic acid, panthenol and its combination on epithelial wound healing in murine corneas. ARVO Abstracts. 2009.
20. Camillieri G., Bucolo C., Rossi S., Drago F. Hyaluronan induced stimulation of corneal wound healing is a pure pharmacological effect. J. Ocul. Pharmacol. Ther. 2004; 20: 548-53.
21. Jiang D., Liang J., Noble P. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011; 91 (1): 221-64.
22. Cyphert J., Trempus C., Garantziotis S. Size matters: molecular weight specificityof Hyaluronan effects in cell biology. J. Cell Biol. 2015; 10: 56388.
23. Ruppert S., Hawn T., Arrigoni A., et al. Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation. Immunol. Res. 2014; 58: 186-92.
24. Horton M., McKee C., Bao C., et al. Hyaluronan fragments synergize with interferon-γ to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages. The J. of Biol. Chem. 1998; 273 (52): 35088-94.
25. Garantziotis S., Li Z., Potts E., et al. Hyaluronan mediates ozone-induced airway hyperresponsiveness in mice. The J. Biol. Chem. 2009; 284 (17): 11309-17.
26. Ludwig A., Van O. Evaluation of sodium hyaluronate as viscous vehicle for eye drops. J. Pharm. Belg. 1989; 44: 391-7.
27. Versura P., Profazio V., Campos E. Performance of tear osmolarity compared to previous diagnostic tests for dry eye disease. Curr. Eye Res. 2010; 35 (7): 553-64.
28. Iester M., Orsoni G., Gamba G., et al. Improvement of the ocular surface using hypotonic 0.4% hyaluronic acid drops in keratoconjunctivitis sicca. Eye. 2000; 14: 892-8.
29. Troiano P., Monaco G. Effect of hypotonic 0.4 % hyaluronic acid drops in dry eye patients: a cross-over study. Cornea. 2008; 27(10): 1126-30.
30. Schrage N., Wuestameyer H., Langefeld S.Do different osmolar solutions change the epithelial surface of the healthy rabbit cornea? Graefs Arch. Clin. Exp. Ophthalmol. 2004; 242 (8): 668-73.
31. Pfister R., Burstein N. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest. Ophthalmol. 1976; 15: 246-59.
32. Rigal D. Die Wirkung von Konservierungsmitteln auf das Auge. Contactologia. 1996; 18: 36-9.
33. Müller-Lierheim W. Neues über Hyaluron säure in Tränener satz lösungen.Ophthalmol. Nachricht. 2014; 12: 22-3.
34. Noecker R., Herrygers L. Effect of preservatives in chronic ocular therapy. Clin. Surg. J. Ophthalmol. 2003; 1(21): 88-94.
35. Teping C., Wiedemann B. Das COMOD system. Eine konservierungs mittle freies Mehr dosebehaltnis f ür Augentropfen. Klin. Monbl. Augenheilkd. 1994; 205: 210-7.
36. López-García J., García-Lozano I. Use of Containers with Sterilizing Filter in Autologous Serum Eyedrops. Ophthalmology. 2012; 119: 2225-30.
37. Marx D., Birkhoff M. New Devices for Dispensing Ophthalmic Treatments May Be the Key to Managing the Life Cycles of Established Products. Drug Deliv. Technol. 2010; 10(9): 16-21.
38. Burstein N. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv. Ophthalmol. 1980; 25: 15-30.
39. Bernauer W., Thiel M., Kurrer M., et al. Corneal calcification following intensified treatment with sodium hyaluronate artificial tears. Br. J. М. Ophthalmol. 2006; 90: 285-8.
40. Daly M., Tuft S., Munro P. Acute corneal calcification following chemical injury. Cornea. 2005; 24: 761-5.
41. Schrage N., Schloßmacher B., Aschenberner W., et al. Phosphate buffer in alkali eye burns as an inducer of experimental corneal calcification. Burns. 2001;27: 459-64.
42. Bernauer W., Thiel M., Langenauer U., Rentsch K. Phosphate concentration in artificial tears.Graefes Arch. Clin. Exp. Ophthalmol. 2006; 244 (8): 1010-4.
43. Haddox J., Pfister R., Yuille Barr D. The efficacy of topical citrate after alkali injury is dependent on the period of time it is administered. Invest. Ophthalmol. Vis. Sci. 1989; 30: 1062-8.
44. Pult H. Trockene Augen: Hyaluron - Augentropfen - Mehrdosis systeme. Der Augenoptiker. 2013; 12: 48-50.
45. Дравица Л.В., Самохвалова Н.М.,Аль хадж Анас Хусейн, Конопляник Е.В. Катионорм в лечении синдрома «сухого глаза» у пациентов с аутоиммунным поражением щитовидной железы. Офтальмология. ВосточнаяЕвропа. 2014; 3(22): 138-46.
46. Морхат М.В., Катульская Т.В., Морхат Е.В. Влияние лекарственного средства окутиарз на динамику толщины роговицы в послеоперационный период неосложнённой факоэмульсификации катаракты. Офтальмология. ВосточнаяЕвропа. 2015; 4 (27): 142-8. Morkhat M., Katulskaya T., Morkhat E. Effects of Ocutears drops usage on corneal thickness in the postoperative period of uncomplicated cataract phacoemulsification. EasternEurope. 2015; 4(27): 142-8 (inRussian).
47. Рожко Ю.И. Окутиарз при синдроме «сухого глаза» у женщин после гистерэктомии. Офтальмология. ВосточнаяЕвропа. 2015; 4(27): 126-40.
48. Рожко Ю.И., Тарасюк Е.А., Глушнев И.А. Окутиарз при дисфункции мейбомиевых желёз: клинический опыт. В кн.: Сборник статей республиканской научно-практической конференции «Инновации в офтальмологии». 2015: 25-6.
49. Бржеский В.В., Егорова Г.Б., Егоров Е.А. Синдром сухого глаза и заболевания глазной поверхности. Москва: ГОЭТАР-Медиа; 2016.
Review
For citations:
Pronkin I.A., Maichuk D.Yu. Artificial tears containing hyaluronic acid in dry eye syndrome treatment. Russian Ophthalmological Journal. 2016;9(4):97-104. (In Russ.) https://doi.org/10.21516/2072-0076-2016-9-4-97-104
Views:
1350
Email this article 